Dimensional Fund Advisors LP raised its stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 10.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,352,329 shares of the oil and gas company's stock after purchasing an additional 122,718 shares during the quarter. Dimensional Fund Advisors LP owned 2.93% of Core Laboratories worth $22,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Core Laboratories by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company's stock valued at $418,000 after buying an additional 1,170 shares in the last quarter. American Century Companies Inc. grew its position in Core Laboratories by 14.3% in the second quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company's stock worth $1,533,000 after acquiring an additional 16,677 shares in the last quarter. Quantbot Technologies LP increased its stake in Core Laboratories by 343.7% in the second quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company's stock valued at $202,000 after acquiring an additional 13,571 shares during the last quarter. Sei Investments Co. bought a new position in Core Laboratories in the second quarter valued at $231,000. Finally, The Manufacturers Life Insurance Company raised its position in Core Laboratories by 6.2% during the second quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company's stock valued at $207,000 after purchasing an additional 1,040 shares in the last quarter. Hedge funds and other institutional investors own 97.81% of the company's stock.
Core Laboratories Trading Up 2.2%
Shares of CLB opened at $11.20 on Friday. Core Laboratories Inc. has a fifty-two week low of $9.72 and a fifty-two week high of $20.36. The firm has a market cap of $513.68 million, a price-to-earnings ratio of 19.99, a PEG ratio of 2.64 and a beta of 1.03. The firm has a 50 day moving average price of $11.76 and a 200-day moving average price of $14.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.55 and a current ratio of 2.12.
Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $124.61 million for the quarter, compared to analyst estimates of $126.26 million. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The firm's quarterly revenue was down 4.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.19 EPS. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. As a group, equities research analysts forecast that Core Laboratories Inc. will post 0.53 earnings per share for the current year.
Core Laboratories Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Monday, August 10th will be paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, August 10th. Core Laboratories's payout ratio is 7.14%.
Insider Buying and Selling at Core Laboratories
In related news, CEO Lawrence Bruno bought 5,000 shares of the company's stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $10.78 per share, for a total transaction of $53,900.00. Following the acquisition, the chief executive officer directly owned 262,438 shares of the company's stock, valued at $2,829,081.64. The trade was a 1.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.26% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on CLB shares. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, August 1st. Weiss Ratings upgraded Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Core Laboratories presently has an average rating of "Hold".
View Our Latest Stock Analysis on CLB
Core Laboratories Profile
(
Free Report)
Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.
The company's portfolio spans two primary service lines: reservoir description and production enhancement.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
